Latest Breaking News On - Marinus pharmaceuticals - Page 1 : comparemela.com

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Autodesk, and Marinus and Encourages Investors to Contact the Firm - Autodesk (NASDAQ:ADSK), Marinus Pharma (NASDAQ:MRNS)

NEW YORK, June 14, 2024 (GLOBE NEWSWIRE) Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of

Bragar Eagel & Squire, P.C. Reminds Investors That Class

NEW YORK, June 14, 2024 (GLOBE NEWSWIRE) Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that.

Law Offices of Howard G. Smith Announces Investigation of Marinus Pharmaceuticals, Inc. (MRNS) on Behalf of Investors

Shareholders with losses of $100,000 or more are encouraged to contact the firm. .

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Marinus Pharmaceuticals, Inc. (MRNS) on Behalf of Investors

Avidity Up 33% on Rare Muscle Disease Study Results - Arcutis Biotherapeutics (NASDAQ:ARQT), Heron Therapeutics (NASDAQ:HRTX)

Avidity Biosciences (NASDAQ: RNA) announced encouraging initial data from the phase I/II FORTITUDE study evaluating two doses of delpacibart braxlosiran (del-brax, or formerly AOC 1020) in facioscapulohumeral muscular dystrophy (FSHD), a rare genetic disease of the muscles.